# A scFv-based immunotoxin for selective targeting and cytotoxicity against c-Met-overexpressing cancer cells: an integrated in silico and in vitro study

Source: [Biological sciences : nature.com subject feeds](https://www.nature.com/articles/s41598-026-80997-x) · 2026-11-17 · Life
Page: https://themorning.science/story/a-scfv-based-immunotoxin-for-selective-targeting-and-cytotoxicity-against-c-met-9390bc64ea7f739f
Kind: research · Impact: low

## In brief

- The study describes a scFv-based immunotoxin designed to selectively target cancer cells that overexpress c-Met.
- The work is reported as an integrated in silico and in vitro study, so its evidence comes from computational modelling and laboratory cell experiments.
- The source summary is not available, so the reported cytotoxicity results cannot be detailed here.

## Why it matters

It is an early-stage preclinical study of a targeted therapy approach against c-Met-overexpressing tumours, which science readers can use to track progress in immunotoxin design.

## Coverage

- [A scFv-based immunotoxin for selective targeting and cytotoxicity against c-Met-overexpressing cancer cells: an integrated in silico and in vitro study](https://www.nature.com/articles/s41598-026-80997-x) — Biological sciences : nature.com subject feeds, 2026-11-17

Tags: immunotoxin, c-met, targeted therapy, scfv, cancer research, in silico

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
